Science Corporation implants its vision-restoring chip in its first Stargardt disease patient
Max Hodak, former president and co-founder of Neuralink, shared details at TechCrunch Disrupt about his company's latest advancement in brain-computer interfaces.
A major milestone has been reached in the field of neurotechnology and healthcare. Max Hodak, the former president and co-founder of Neuralink, took the stage at TechCrunch Disrupt to shed light on his current venture, Science Corporation, and its groundbreaking medical developments.
Hodak detailed how the company's work with the PRIMA system has achieved a critical medical breakthrough by implanting a vision-restoring chip into its very first patient suffering from Stargardt disease.
According to Hodak, this procedure is not just an isolated clinical success but an integral part of a broader pathway toward developing a novel and highly effective brain-computer interface (BCI) technology.
Stargardt disease is an inherited juvenile macular degeneration that causes progressive vision loss. The deployment of advanced visual prosthesis chips offers genuine hope for patients facing severe or complete vision impairment.
For the global tech and medical community, this achievement underscores the accelerating pace of neurotechnology innovation. As BCI research moves closer to commercial and clinical reality, it paves the way for transformative healthcare solutions worldwide.
